Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof
The present invention provides a bispecific antibody capable of being combined with immune cells to enhance a targeting tumor killing capability, and a preparation method therefor and an application thereof. Antibodies and degradable nanoparticles are connected by using a chemical method, so as to make the one nanoparticle be connected to two or more antibody molecules at the same time, wherein one antibody can be specifically bound with immune cells, and the other antibody or the other antibodies can be specifically bound to tumor cells so as to achieve the effect of enhancing the capability of the immune cells for specifically killing tumor cells in a targeting way.
1. A bispecific antibody capable of being combined with an immune cell to enhance a targeting tumor killing capability, wherein the antibody comprises a first antibody moiety that binds to an antigen expressed on an effector T cell and a second antibody moiety that binds to an antigen expressed on a target cell, wherein the first antibody moiety and the second antibody moiety are connected by a nanomaterial which is a biodegradable nanomaterial, wherein the nanomaterial is polylactic acid-glycolic acid, the target cell is a cancer cell, the antigen expressed on the target cell is Muc1, and the antigen expressed on the effector T cell is CD3.
2. A method for producing a bispecific antibody according to claim 1 , which comprises connecting the nanomaterial to the first antibody moiety and the second antibody moiety.
3. The method according to claim 2 , which comprises the steps of: (1) preparation, collection and activation of the nanomaterial; (2) connecting the nanomaterial obtained in step (1) with a mixture of the first antibody moiety and the second antibody moiety.
4. The method according to claim 3 , wherein the nanomaterial is polylactic acid-glycolic acid and the solvent is any one of acetone, butanone, methanol, ethanol or isopropanol or a mixture thereof.
5. A method of treating a tumor in a subject comprising administering to the subject a bispecific antibody according to claim 1 .
6. The method according to claim 5 , wherein the tumor is selected from the group consisting of liver cancer, non-small cell lung cancer, small cell lung cancer, adrenocortical carcinoma, acute (chronic B) lymphocytoma, myeloma, prostate cancer, breast cancer, esophageal cancer, gastric cancer, colorectal cancer, cervical cancer, kidney cancer, bladder cancer and lymphoma.